每周一次对比隔日一次前列腺癌立体定向放疗(PATRIOT):2期随机试验
这项多中心2期随机试验将低危和中危前列腺癌患者随机分配至40 Gy/5次每周一次(QW)或隔日一次(EOD)方案,以比较整体治疗时间对生活质量的影响。结果显示QW组急性肠道和泌尿生活质量优于EOD组,但2年或末次随访时晚期生活质量无显著差异。
要点
- QW组急性肠道QOL最小临床重要改变(MCIC)比例低于EOD组(68% vs 90%,p=0.002)。
- QW组急性期中重度肠道问题比例低于EOD组(20% vs 57%,p<0.001)。
- QW组急性泌尿QOL的MCIC比例也低于EOD组(78% vs 94%,p=0.006)。
核心结论
- 前列腺SBRT每周一次给药较隔日一次可改善急性肠道和泌尿生活质量,应告知患者每周方案可能减少短期毒性并改善生活质量。
研究设计与样本
- 多中心、随机、2期研究,纳入低危和中危前列腺癌男性,随机分配至40 Gy/5次每周一次(QW)或隔日一次(EOD),主要终点为急性期(≤12周)肠道生活质量最小临床重要改变(MCIC)比例,按意向性分析。
主要发现
- 共152例来自3个中心随机,中位随访47个月。
- QW组急性肠道QOL的MCIC为47/69(68%),EOD组为63/70(90%),p=0.002。
- QW组急性期中重度肠道问题为14/70(20%),EOD组为40/70(57%),p<0.001。
- QW组急性泌尿QOL的MCIC为52/67(78%),EOD组为65/69(94%),p=0.006。
- 2年或末次随访时晚期泌尿或肠道QOL无显著差异。
关键数值与推荐
- QW方案为40 Gy分5次每周一次,EOD方案为40 Gy分5次隔日一次。
- 急性期定义为≤12周;MCIC采用Expanded Prostate Cancer Index Composite评估。
临床怎么用
- 对于低危和中危前列腺癌患者,可考虑采用每周一次SBRT方案以降低急性肠道和泌尿毒性并改善短期生活质量。
- 应与患者沟通每周一次方案在减少短期毒性和改善生活质量方面的潜在优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Prostate stereotactic body radiotherapy (SBRT) regimens differ in time, dose, and fractionation. We completed a multicentre, randomized phase II study to investigate the impact of overall treatment time on quality of life (QOL). MATERIAL AND METHODS: Men with low and intermediate-risk prostate cancer were randomly assigned to 40 Gy in 5 fractions delivered once per week (QW) vs. every other day (EOD). QOL was assessed using the Expanded Prostate Cancer Index Composite. The primary endpoint was the proportion with a minimum clinically important change (MCIC) in bowel QOL during the acute (≤12 week) period, and analysis was by intention-to-treat. ClinicalTrials.gov NCT01423474. RESULTS: 152 men from 3 centres were randomized with median follow-up of 47 months. Patients treated QW had superior acute bowel QOL with 47/69 (68%) reporting a MCIC compared to 63/70 (90%) treated EOD (p = 0.002). Fewer patients treated QW reported moderate-severe problems with bowel QOL during the acute period compared with EOD (14/70 [20%] vs. 40/70 [57%], p < 0.001). Acute urinary QOL was also better in the QW arm, with 52/67 (78%) vs 65/69 (94%) experiencing a MCIC (p = 0.006). There were no significant differences in late urinary or bowel QOL at 2 years or last follow-up. CONCLUSION: Prostate SBRT delivered QW improved acute bowel and urinary QOL compared to EOD. Patients should be counselled regarding the potential for reduced short-term toxicity and improved QOL with QW prostate SBRT.
引用
- Quon HC, Ong A, Cheung P, et al. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial. Radiother Oncol. 2018. PMID: 29551231. doi:10.1016/j.radonc.2018.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。